#Cassiopeia meaning free#
Primary endpoint was stringent complete response (sCR) rate at Day 100 post-transplant: CR + normal free light-chain ratio + absence of clonal plasma cells + disappearance of all plasmacytomas 1–3.On the days of DARZALEX ® infusion, the dexamethasone dose was administered intravenously as a pre-infusion medication. Dexamethasone 20 mg was administered on Days 1, 2, 8, 9, 15, 16 in Cycles 5–6.
VTd dosing and administration: Bortezomib (V) SC or IV, 1.3 mg/m2 BSA twice weekly for 2 weeks on Days 1, 4, 8, 11 of repeated 28-day (4-week) induction cycles (Cycles 1–4) and 2 consolidation cycles (Cycles 5–6) thalidomide (T) PO, 100 mg daily during the 6 bortezomib cycles dexamethasone (d) PO or IV, 40 mg on Days 1, 2, 8, 9, 15, 16, 22, 23 of Cycles 1 and 2, and at 40 mg on Days 1–2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3–4. The efficacy and safety of this maintenance regimen is currently being evaluated 2ĭARZALEX ® dosing and administration: IV, 16 mg/kg actual body weight QW Cycles 1–2 and Q2W Cycles 3–4 (induction phase) Q2W Cycles 5–6 (consolidation phase). In an ongoing part 2 of the study, patients underwent a second randomization in both treatment groups to either observation or DARZALEX ® Q8W monotherapy for maintenance. DARZALEX ® IMPORTANT SAFETY INFORMATION.DARZALEX FASPRO ® IMPORTANT SAFETY INFORMATION.DARZALEX FASPRO ® PRESCRIBING INFORMATION.
0 kommentar(er)
